Search Results

Rezolute, Inc. for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.

May 30, 2024

·

1 min read

Press Releases

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

February 4, 2025

·

7 min read

Press Releases

Rezolute to Participate in Upcoming November 2024 Investor Conferences

November 6, 2024

·

1 min read

Press Releases

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 8, 2025

·

6 min read

Business

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today reported financial results and provided a business update for the three months ended March 31, 2024.

May 15, 2024

·

8 min read

Pharm Country

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - June 13, 2024

Rezolute, Inc., a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, announced that it is commencing an underwritten public offering of shares of its common stock.

June 13, 2024

·

4 min read